홍역, 볼거리, 풍진 백신 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2024-2032년)

Growth Factors of measles, mumps, rubella (MMR) vaccines Market

The global measles, mumps, rubella (MMR) vaccines market is expanding rapidly due to rising infectious disease prevalence, increasing global immunization efforts, and strong support from major health organizations. According to the report, the market size was USD 5.06 billion in 2024, is expected to increase to USD 5.17 billion in 2025, and reach USD 11.01 billion by 2032, exhibiting a CAGR of 11.4% during the forecast period. In 2024, North America held the largest share at 37.15%, driven by robust public health systems and high vaccination coverage.

MMR vaccines protect against three highly contagious viral diseases-measles, mumps, and rubella-using weakened live viruses to induce immunity. Administered in two doses, typically at 12 months and again at 4 years of age, these vaccines demonstrate strong effectiveness. CDC data published in January 2025 shows the first MMR dose is 93% effective against measles, 72% effective against mumps, and 97% effective against rubella, supporting their continued global adoption. Increasing R&D activities by vaccine manufacturers such as GSK plc., Serum Institute of India Pvt. Ltd., and Merck & Co., Inc. further accelerate market progress.

Market Dynamics

Drivers

Government-backed immunization programs are a major driver of global MMR vaccine demand. Countries such as the U.S. and India have integrated MMR into national immunization schedules, ensuring widespread availability for eligible children. Global organizations, including WHO and Gavi, amplify these efforts through financial and logistical support. For example, in May 2025, Gavi reported supporting measles-rubella catch-up campaigns in multiple countries before MR vaccines were added to routine immunization.

Restraints

Vaccine hesitancy remains one of the most significant barriers to market growth. Factors such as misinformation, misconceptions about side effects, and distrust in healthcare systems reduce vaccine acceptance. According to an October 2023 publication by the National Center for Biotechnology Information, many parents avoided MMR vaccination due to concerns about fever and injection-site pain, demonstrating the influence of perceived risks on uptake.

Opportunities

Technological advancements such as microarray patches (MAPs) create significant opportunities for needle-free, thermostable, and easy-to-administer MMR vaccines. These innovations improve compliance, especially in low-income regions with limited healthcare access. UNICEF and WHO began developing microarray patches in collaboration with partners in 2019, offering a strong pathway for future adoption.

Challenges

Maintaining cold chain integrity presents an ongoing challenge. MMR vaccines are extremely sensitive to temperature fluctuations, and improper handling can reduce efficacy and increase wastage. A September 2024 CDC Foundation report confirmed the measles vaccine's high vulnerability to temperature variations, highlighting cold-chain limitations in many regions.

Market Trends

A key trend shaping the MMR vaccine market is the rise in public-private partnerships aimed at addressing immunization gaps. These collaborations enhance distribution, improve vaccine logistics, and strengthen community engagement. Gavi data published in May 2025 showed that USD 55 million was allocated to the Measles & Rubella Initiative between 2013 and 2017, demonstrating long-term financial commitment to disease control.

Segmentation Insights

By Type

The combination vaccine segment dominated in 2024 due to its convenience, cost-effectiveness, and ability to protect against all three diseases through a single injection. FDA approval of GSK's Priorix in June 2022 further strengthened segment growth.

By Product

M-M-R II led the market in 2024, supported by more than 231 million doses sold in the U.S. over 30 years, indicating long-proven global usage. PRIORIX is expected to grow rapidly due to its wide regulatory approvals and strong clinical evidence.

By Route of Administration

The subcutaneous route accounted for the largest share in 2024, as most MMR vaccines-including M-M-R II and PRIORIX-are approved for SC administration.

By Age Group

The pediatric segment held the highest share in 2024 due to heightened susceptibility of children and strong inclusion of MMR in childhood immunization schedules.

By Distribution Channel

Government suppliers dominated due to large-scale procurement for national immunization programs. UNICEF procured 181 million MR vaccine doses in 2021 on behalf of 35 countries.

Regional Outlook

In 2024, North America generated USD 1.88 billion, driven by strong vaccination infrastructure and public health initiatives. The U.S. leads the region with comprehensive immunization policies and continuous disease monitoring. Europe holds a strong share due to mandatory two-dose schedules across EU/EEA countries. Asia Pacific is the fastest-growing region due to expansions of national immunization programs and free vaccine administration under initiatives such as India's Universal Immunization Programme (UIP). Latin America and Middle East & Africa show steady growth supported by rising awareness and improving healthcare access.

Conclusion

Expanding from USD 5.06 billion in 2024 to USD 11.01 billion by 2032, the MMR vaccines market is set for strong growth through improved awareness, technological innovation, public-private collaborations, and strengthened immunization programs worldwide.

Segmentation By Type

• Standalone
• Combination

By Product

• M-M-R II
• PRIORIX
• M-M-RvaxPro
• Tresivac
• Others

By Route of Administration

• Intramuscular
• Subcutaneous
• Others

By Age Group

• Adult
• Pediatric

By Distribution Channel

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Region

• North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Overview: Immunization Coverage, By Key Countries
• 4.4. Technological Advancements in the MMR Vaccines
• 4.5. New Product Launches, By Key Players
• 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Standalone
  • 5.1.2. Combination
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. M-M-R II
  • 5.2.2. PRIORIX
  • 5.2.3. M-M-RvaxPro
  • 5.2.4. Tresivac
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Intramuscular
  • 5.3.2. Subcutaneous
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Age Group
  • 5.4.1. Pediatrics
  • 5.4.2. Adults
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital & Retail Pharmacies
  • 5.5.2. Government Suppliers
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Standalone
  • 6.1.2. Combination
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. M-M-R II
  • 6.2.2. PRIORIX
  • 6.2.3. M-M-RvaxPro
  • 6.2.4. Tresivac
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Intramuscular
  • 6.3.2. Subcutaneous
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Age Group
  • 6.4.1. Pediatrics
  • 6.4.2. Adults
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital & Retail Pharmacies
  • 6.5.2. Government Suppliers
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Standalone
  • 7.1.2. Combination
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. M-M-R II
  • 7.2.2. PRIORIX
  • 7.2.3. M-M-RvaxPro
  • 7.2.4. Tresivac
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Intramuscular
  • 7.3.2. Subcutaneous
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Age Group
  • 7.4.1. Pediatrics
  • 7.4.2. Adults
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital & Retail Pharmacies
  • 7.5.2. Government Suppliers
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Standalone
  • 8.1.2. Combination
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. M-M-R II
  • 8.2.2. PRIORIX
  • 8.2.3. M-M-RvaxPro
  • 8.2.4. Tresivac
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Intramuscular
  • 8.3.2. Subcutaneous
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Age Group
  • 8.4.1. Pediatrics
  • 8.4.2. Adults
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital & Retail Pharmacies
  • 8.5.2. Government Suppliers
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Standalone
  • 9.1.2. Combination
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. M-M-R II
  • 9.2.2. PRIORIX
  • 9.2.3. M-M-RvaxPro
  • 9.2.4. Tresivac
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Intramuscular
  • 9.3.2. Subcutaneous
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Age Group
  • 9.4.1. Pediatrics
  • 9.4.2. Adults
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital & Retail Pharmacies
  • 9.5.2. Government Suppliers
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2019-2032

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Standalone
  • 10.1.2. Combination
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. M-M-R II
  • 10.2.2. PRIORIX
  • 10.2.3. M-M-RvaxPro
  • 10.2.4. Tresivac
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Intramuscular
  • 10.3.2. Subcutaneous
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Age Group
  • 10.4.1. Pediatrics
  • 10.4.2. Adults
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital & Retail Pharmacies
  • 10.5.2. Government Suppliers
  • 10.5.3. Others
• 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 10.6.1. GCC
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2024)
• 11.2. Company Profiles
  • 11.2.1. GSK plc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. Serum Institute of India Pvt. Ltd.
    • 11.2.2.1. Overview
    • 11.2.2.2. Products
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. Merck & Co., Inc.
    • 11.2.3.1. Overview
    • 11.2.3.2. Products
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Indian Immunologicals Limited
    • 11.2.4.1. Overview
    • 11.2.4.2. Products
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Zydus Lifesciences Limited
    • 11.2.5.1. Overview
    • 11.2.5.2. Products
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Takeda Pharmaceutical Company Limited
    • 11.2.6.1. Overview
    • 11.2.6.2. Products
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. BIOLOGICAL E. LIMITED
    • 11.2.7.1. Overview
    • 11.2.7.2. Products
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Invivyd, Inc.
    • 11.2.8.1. Overview
    • 11.2.8.2. Products
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Daiichi Sankyo Company, Limited
    • 11.2.9.1. Overview
    • 11.2.9.2. Products
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)